Remove Botox Remove FDA Approval Remove Marketing
article thumbnail

Allergan Aesthetics and BOTOX® Cosmetic (onabotulinumtoxinA) Put Real Stories at the Forefront in New Campaign

The Pharma Data

June 8, 2021 /PRNewswire/ — Allergan Aesthetics, an AbbVie company (NYSE: ABBV ), is changing the way BOTOX ® Cosmetic, the #1 selling neurotoxin treatment 1 , is connecting with consumers. “BOTOX ® Cosmetic is honoring and celebrating the dynamic people who use our products. IRVINE, Calif.

Botox 52
article thumbnail

AbbVie’s Qulipta cleared for migraine prevention, setting up Biohaven clash

pharmaphorum

AbbVie has added a third drug to its arsenal in the crowded migraine market, getting FDA approval for Qulipta – its once-daily oral preventive therapy for episodic migraines. AbbVie acquired Qulipta in 2020 as part of its $63 billion takeover of Allergan, which also brought in Botox and Ubrelvy.

Botox 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

GW Pharma Hopes to Bring Its Second Cannabis-Based Drug to Market in the U.S.

The Pharma Data

There are a few medications approved to treat spasticity, including the generic baclofen and Botox. The FDA is expected to make a decision on Osmotica Pharmaceuticals’ arbaclofen extended release tablets for MS-associated spasticity in December. It also forced the U.S.

article thumbnail

U.S. FDA Accepts AbbVie’s New Drug Application for Atogepant for the Preventive Treatment of Migraine

The Pharma Data

2] – The atogepant application demonstrates AbbVie’s longstanding commitment to providing multiple migraine treatment options, including BOTOX® (onabotulinumtoxinA), a preventive treatment for those with chronic migraine, and UBRELVY® (ubrogepant), an acute treatment for adults with migraine. IMPORTANT SAFETY INFORMATION.

Botox 52
article thumbnail

Top 10 Pharma and Biotech M&As in the Past Decade

XTalks

Among these, mergers and acquisitions (M&As) have played a pivotal role in reshaping the industry landscape, enabling companies to bolster their portfolios, enhance R&D capabilities and expand their global market reach. Following the merger, Actavis rebranded itself as Allergan, leveraging the strong recognition of Allergans brand.

Marketing 104
article thumbnail

Top 30 Drugs to Watch in 2024: Insights from 2023 Sales Data

XTalks

This journey through the pharmaceutical market will provide valuable insights into the trends shaping the healthcare industry and the innovations that continue to push the boundaries of medical science. Keytruda also won just under half a dozen FDA approvals in new oncology indications.

Sales 40
article thumbnail

AbbVie Reports Second-Quarter 2021 Financial Results

The Pharma Data

Global Botox Therapeutic net revenues were $603 million, an increase of over 100.0 Global Botox Cosmetic net revenues were $584 million, an increase of over 100.0 The FDA cited its ongoing review of Pfizer’s post-marketing study, ORAL Surveillance, evaluating tofacitinib in patients with rheumatoid arthritis (RA).

Botox 52